Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences
- 4 March 2019
- journal article
- research article
- Published by Taylor & Francis in AIDS Care
- Vol. 31 (11) , 1340-1347
Abstract
HIV/HCV coinfected patients are a priority for direct acting antiretroviral (DAA) treatment, yet barriers to treating vulnerable patients persist. This study surveyed safety net clinic patients and providers to quantify their preferences for DAA treatment and prioritize modifiable barriers. Preferences were assessed using best-worst scaling. General linear mixed models were used to determine whether attributes differed in importance and whether patients and providers valued attributes differently. 158 HIV/HCV coinfected patients and 49 providers participated. Patients and providers had strong preferences for treatment within the medical homes where patients receive HIV care. Support such as reminders and advice numbers were also important, but were more important to providers than patients. Providers identified lack of insurance coverage for DAA as the most significant barrier. Providers rated HIV primary care providers as best suited to deliver DAA to HIV+ patients. Addressing structural barriers is essential for increasing DAA treatment in safety net settings.Keywords
Funding Information
- National Institute on Drug Abuse (5UM1AI068636, K24DA039780, K24DA037034)
- National Institute of Allergy and Infectious Diseases (UM1AI106701, UM1AI069496)
This publication has 31 references indexed in Scilit:
- Expanding Capacity for Hepatitis C Treatment in the United StatesJournal of the International Association of Providers of AIDS Care (JIAPAC), 2015
- Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation ProgramJournal of General Internal Medicine, 2015
- The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategiesScandinavian Journal of Gastroenterology, 2014
- Patients’ Willingness to Accept the Risks and Benefits of New Treatments for Chronic Hepatitis C Virus InfectionThe Patient - Patient-Centered Outcomes Research, 2012
- HIV Coinfection With Hepatitis C Virus: Evolving Epidemiology and Treatment ParadigmsClinical Infectious Diseases, 2012
- Hepatitis C Virus and the Infectious Disease Physician: A Perfect MatchClinical Infectious Diseases, 2012
- Patient preferences and assessment of likely adherence to hepatitis C virus treatmentJournal of Viral Hepatitis, 2010
- Hepatitis C Treatment Experiences and Decision Making Among Patients Living With HIV InfectionJournal of the Association of Nurses in AIDS Care, 2009
- Patients’ Preferences for Treatment of Hepatitis CMedical Decision Making, 2009
- Challenges in the Treatment of Patients Coinfected with HIV and Hepatitis C Virus: Need for Team CareClinical Infectious Diseases, 2005